Lynozyfic Monotherapy Shows Promising Efficacy in Newly Diagnosed Multiple Myeloma Patients
核心洞察
Regeneron's LINKER-MM4 Phase 1/2 trial demonstrated that Lynozyfic monotherapy achieved ≥70% very good partial response rates across all dose groups in newly diagnosed multiple myeloma (搜索) patients.
The study represents the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in newly diagnosed multiple myeloma (搜索), with 95% of evaluable patients achieving minimal residual disease negativity.
Results were presented at the American Society of Hematology Annual Meeting, supporting Lynozyfic's potential as a foundational treatment component that could simplify current complex combination regimens.
Regeneron Pharmaceuticals announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) monotherapy in adults with newly diagnosed multiple myeloma (搜索) (NDMM) at the American Society of Hematology Annual Meeting. The study represents the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in this patient population and demonstrated impressive efficacy across all tested dose levels.
Trial Design and Patient Population
LINKER-MM4 is an ongoing, open-label Phase 1/2 trial investigating Lynozyfic in adults with NDMM. The study enrolled 45 patients across Phase 1A (dose escalation) and Phase 1B (dose expansion) cohorts, with 28 patients being transplant eligible and 17 transplant ineligible. During Phase 1A, patients received step-up dosing followed by 50 mg, 100 mg, or 200 mg doses of Lynozyfic, with the lowest and highest tolerated doses selected for further evaluation in Phase 1B.
Efficacy Results
All three dose groups (50 mg, 100 mg, and 200 mg) demonstrated impressive monotherapy efficacy, achieving very good partial response or better (VGPR+) rates of ≥70% despite limited follow-up. The median time to onset of response across all dose levels was 1.2 months (range: 1-4.5 months). Evidence indicates these responses are expected to deepen over time.
Particularly noteworthy was the minimal residual disease (MRD) negativity data. Across all dose groups, 95% (19 of 20 patients) of all MRD evaluable VGPR+ patients achieved MRD negative status at 10⁻⁵ sensitivity, a rate comparable to quadruplet regimens but achieved earlier in the treatment course.
Safety Profile
The most common treatment-emergent adverse events were cytokine release syndrome (CRS; all Grade 1: 44%) and neutropenia (any Grade: 38%; Grade 3/4: 33%). One patient in the 50 mg cohort experienced Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS). Infections occurred in 84% of patients (Grade 1/2: 51%; Grade 3: 33%), with the majority occurring within the first three months of treatment and decreasing over time. Importantly, there were no ≥Grade 4 infections, Grade 5 treatment-emergent adverse events, or dose-limiting toxicities.
Ten patients elected to undergo autologous stem cell transplant, all achieving acceptable CD34+ stem cell yields post-induction (range: 2.5-11.5 x 10⁶/kg).
Clinical Significance
"The treatment of newly diagnosed multiple myeloma (搜索) often relies on complicated combinations of quadruplet or triplet regimens, each with its own toxicities, in order to achieve rapid and durable responses, which can be incredibly burdensome for these patients," said Robert Orlowski, M.D., Ph.D., lead investigator for the LINKER-MM4 trial and Deputy Chair, Professor of Medicine, and Director of Translational Myeloma Research at The University of Texas MD Anderson Cancer Center.
Dr. Orlowski emphasized that LINKER-MM4 seeks to understand whether frontline intervention with a single agent can deliver strong efficacy, enabling simplification and potentially greater tolerability of treatment regimens. "Lynozyfic monotherapy is already achieving MRD negativity rates comparable to quadruplet regimens but earlier in the treatment course, and these compelling results are expected to deepen with longer follow up," he noted.
Broader Development Program
The LINKER-MM4 results are part of a comprehensive clinical development program evaluating Lynozyfic in early lines of treatment. This includes the Phase 2 portion of LINKER-MM4 evaluating Lynozyfic at the recommended 200 mg dose, as well as LINKER-MM6 (EMN39), a trial evaluating a combination of daratumumab, lenalidomide and dexamethasone followed by Lynozyfic monotherapy compared with continued combination therapy in transplant-ineligible NDMM.
About Lynozyfic and Multiple Myeloma
Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (搜索) (BCMA (搜索)) on multiple myeloma (搜索) cells with CD3 (搜索)-expressing T cells to facilitate T-cell activation and cancer-cell killing. The drug was developed using Regeneron's VelocImmune technology and is currently approved to treat certain adults with relapsed/refractory multiple myeloma (搜索) after four lines of therapy in the U.S. and after at least three prior therapies in the European Union.
Multiple myeloma (搜索) is the second most common blood cancer, with over 187,000 new cases diagnosed globally each year and more than 36,000 diagnosed with 12,000 deaths anticipated in the U.S. in 2025. The disease is characterized by the proliferation of cancerous plasma cells that crowd out healthy blood cells in the bone marrow, infiltrate other tissues, and cause potentially life-threatening organ injury. Despite treatment advances, multiple myeloma is not curable, and most patients will ultimately experience cancer progression requiring additional therapies.